Pharmaceuticals & Biotech Belgian Community

argenx is betting that its lead drug VYVGART can move beyond one rare disease and become a platform treatment across several autoimmune conditions. The upside comes from a steady stream of upcoming study results and new uses, but the story can also break if trials disappoint or drug-pricing pressure intensifies.Read more

argenx is pushing its lead autoimmune drug into more uses and more countries, with a self‑injection option that could make it easier for patients to start and stay on treatment. The big question is whether growing competition and tougher rules around drug pricing and insurance coverage start to squeeze what the company can earn.Read more

UCB faces a rough stretch as drug price cuts and upcoming copycat competition threaten some of its biggest medicines, making it harder to keep sales and profits growing. At the same time, its newer launches and late-stage treatments could keep the business moving forward if they reach patients quickly and gain traction.Read more

argenx leans heavily on its Vyvgart medicine, and growing pushback on drug pricing plus copycat alternatives could squeeze what it earns on each patient over time. At the same time, new treatments in development and investments in making and delivering its drugs could help it rely less on one product and keep growth going.Read more

argenx’s lead treatment for autoimmune disease is catching on faster than many expected, helped by an easier way to take it and new uses rolling out in more countries. The bigger story is whether its new AI-aided research push and growing demand from an aging population can keep growth going even as pricing, regulators, and new rivals raise the stakes.Read more

UCB is pushing into hard-to-treat brain and immune diseases with new medicines, and early signs suggest these launches could keep growth going even as older drugs face more competition. See what could help the company scale up—and what could trip it up, from tougher pricing talks to drug patents running out.Read more

Key Takeaways Rapid adoption of innovative therapies and expanded indications position UCB for sustained, above-industry revenue and earnings growth amid rising global demand for specialty treatments. Ongoing digitalization, operational leverage, and a shift to higher-margin products are boosting profitability, setting the stage for continued margin expansion and market share gains.Read more

Catalysts About MDxHealth MDxHealth provides precision molecular diagnostics that guide urology clinicians and patients through the full prostate cancer diagnostic pathway. What are the underlying business or industry changes driving this perspective?Read more